Chemical Biology of Pluripotent Stem Cells: Focus on Cardiomyogenesis by Jijun Hao et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
3 
Chemical Biology of Pluripotent Stem Cells:  
Focus on Cardiomyogenesis 
Jijun Hao2, Li Zhou2 and Charles C. Hong1,2,3,4,5,6  
1Research Medicine, Veterans Affairs TVHS, Nashville, TN 37212 
2Division of Cardiovascular Medicine, Department of Medicine, 
3Department of Pharmacology, 
4Departmetn of Cell and Developmental Biology, 
5Vanderbilt Institute of Chemical Biology, 
6Vanderbilt Center for Stem Cell Biology, 
Vanderbilt University School of Medicine, Nashville, TN 37232,  
USA 
1. Introduction 
Heart disease is one of the leading killers in the world and accounts for 36% of all deaths in 
the United States. Unlike many other organs, the heart lacks the capacity to significantly 
regenerate new tissues to replace those lost to injury. Consequently, ischemia, viral 
infection, or other insults can lead to permanent loss of cardiac tissue and irreversible heart 
failure. Currently, the only definitive treatment for heart failure is heart transplantation, 
which is precluded from wider use due to the limited availability of donor organs.  In the 
past several years, stem cell-based regenerative therapy has emerged as a potentially 
promising approach to treat heart failure.  Its basic goal is to replace the damaged non-
contractile scar tissue with functioning cardiomyocytes derived from pluripotent or 
multipotent stem cells.  For many years, it was generally believed that heart is a terminally 
differentiated organ lacking capacity to replace cardiomyocytes lost to injury.  Recent 
studies, however, have provided evidence for limited cardiomyocyte renewal in both mice 
and humans [1, 2].  Moreover, major inroads have been made towards understanding the 
nature of endogenous progenitor cells within the heart [3-5]. Although the definitive 
identification of the cardiac progenitor cells remains elusive, evidence of the heart’s 
regenerative capacity, however minimal, gives hope that cell-based therapies could become 
a viable approach to treat human heart failure. 
Among the various cell types considered for transplantation, the pluripotent embryonic 
stem cells (ESCs) are thought to be most suitable for the role of potentially unlimited 
reservoir of replacement cells given their ability to differentiate into any cell type in the 
body, including vascular and heart muscle cells. Following the isolation of the first human 
embryonic stem cell (hESC) line in 1998 [6], there has been intense interest in trying to direct 
differentiation of ES cells toward cardiovascular lineages, with the ultimate goal of using 
hESC-derived cardiomyocytes for transplantation. However the use of hESCs faces two 
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major obstacles:  1) the ethical issues concerning the use of human fertilized embryos, and 2) 
immune rejection following transplantation. In light of this, there has been tremendous 
excitement over the recent development of induced pluripotent stem cells (iPSCs).  In 2006, 
Yamanaka and colleagues demonstrated that introduction of four transcription factors 
(Sox2, Oct4, Klf4 and c-Myc) into fibroblasts could reprogram these cells into pluripotent 
iPSCs that closely resemble ESCs [7]. Cellular reprogramming has potential to revolutionize 
the field of regenerative medicine, since iPSCs engineered from a patient’s own cells could 
circumvent the core ethical and immune rejection problems associated with human ES cells.  
The discoveries of endogenous regenerative processes and iPSCs raise hope not only for 
replacement of damaged heart tissues with patient-derived cardiomyocytes but also for 
development of new cellular models to study the pathogenesis of human heart diseases  
[7-12].  
Despite these advances, the future use of pluripotent stem cells for diagnosis and therapy 
faces a number of major obstacles. For instance, the stem cell field in general has been 
hampered by lack of simple and robust methodologies that give consistent results.  Current 
methods typically utilize exogenous proteins and feeder cell layers to maintain the 
pluripotency of stem cells. While traditional culture conditions are amenable to typical 
laboratory use, the dependence on expensive biological reagents limits the scale to which 
these cells can be cultured. Furthermore, there is often considerable variability associated 
with the use of growth factors, cytokines and protein antagonists. In many respects, small 
molecules are superior to conventional protein effectors: they are far less expensive and 
often yield more reproducible results. Finally, from industrial and biotechnological 
perspectives, small molecules are attractive intellectual property assets that can provide 
protection of investments in regenerative medicine. These issues have helped to set the stage 
for the development of small molecular modulators for use in stem cell field. In this chapter, 
we will provide an overview of the use of small molecules for stem cell maintenance, 
cellular reprogramming and directed differentiation, with a focus on cardiomyocyte 
formation.   
2. Role of small molecules in stem cell field.  
A. Small molecules for stem cell maintenance. 
As previously mentioned, an important challenge of using pluripotent stem cells involves 
devising culture conditions that ensure self renewal through the maintenance of both 
proliferative capacity and pluripotency.  ES cells are traditionally maintained on an 
inactivated mouse embryonic fibroblast feeder layer in medium containing undefined 
animal serum and exogenous proteins.  For example, mouse ES cells (mESCs) require LIF 
(Leukemia Inhibitory Factor) to inhibit differentiation and promote cell cycle progression.  
Human ES cells (hESCs), which are unresponsive to LIF, require Transforming growth 
factor-β (TGF-β)/Nodal and Basic Fibroblast Growth Factor (bFGF) for maintaining 
pluripotency [13].   
An important issue with the traditional methods of  maintaining pluripotent stem cells 
involves the use of undefined animal serum and feeder layers, which can produce variable 
and heterogeneous results.  Moreover, the use of animal serum products precludes clinical 
applications given the potential for xenoantigen introduction [14].  To overcome these 
obstacles, a number of serum and feeder replacement media formulations have been 
developed.  These include KnockOut Serum Replacement, a defined media, which provides 
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consistent growth conditions for maintaining ES and iPS cells [15], and mTeSR, a media 
specifically formulated to maintain human ESCs and iPSCs in serum-free and feeder-free 
conditions [16].  However, both KnockOut Serum Replacement and mTeSR require the use 
of animal-derived matrices and recombinant proteins, which increase costs and introduce 
variability [14, 17]. Consequently, there has been considerable interest in replacing 
exogenous proteins with chemically defined conditions for the long-term maintenance of 
human pluripotent stem cells. 
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Fig. 1. Application of small molecules for stem cell-based efforts in cardiology. 
Small molecules to 1) enhance reprogramming of adult somatic tissues into pluripotent stem 
cells, 2) maintain pluripotent stem cells in culture, and 3) promote cardiac differentiation of 
stem cells will be valuable for harnessing the full potential of stem cells in regenerative 
therapy, human cardiac tissue-based diagnostics, and drug discovery. 
In a high-throughput chemical screen, Ding and colleagues identified a novel molecule, 
Pluripotin/SC1, which was useful for maintaining long-term self-renewal of mouse ES cells 
(mESCs) in the absence of a feeder layer, serum, leukemia inhibitory factor (LIF) or BMP4  
[18]. The mechanism of action was found to be independent of known self-renewal 
pathways thought to be essential (BMP4/Smad-Id [19], Wnt/B-catenin [20], LIF/STAT3 
[21]). Instead, pluripotin was characterized as a dual inhibitor of extracellular signal-
regulated kinase-1 (ERK1) and RasGAP, two differentiation-inducing proteins.  Blocking 
RasGAP improves the self-renewal capabilities of ES cells by enhancing the phophonositide-
3 kinase (PI3K) pathway [22]. In contrast, ERK1 inhibition works by blocking ES cell 
differentiation [23, 24].   
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The pluripotin discovery has important implications for stem cell renewal. The mechanism 
of action of pluripotin suggests that pluripotency of ES cells can be maintained simply by 
inhibiting the endogenous activity of differentiation-inducing proteins, rather than also 
activating specific self-renewal pathways.  Thus, inhibiting the effects of endogenously 
expressed inducers of cell death and differentiation may be sufficient for ES cell self-
renewal.  This hypothesis is supported by a study by Ying et al [25], in which a combination 
of glycogen synthase kinase-3 (GSK-3) inhibitor, CHIR99021 and mitogen-activated protein 
kinase (MEK) inhibitor, PD0325901, could maintain long-term self-renewal of mESCs in the 
absence of exogenous cytokines [25]. Other small molecules which has been used to 
maintain mouse ES cells in pluripotent state include PD98059, a MEK inhibitor, 6-
Bromoindirubin-3’-oxime (BIO), another GSK-3 inhibitor/Wnt signaling activator, and IQ-1, 
a modulator of Wnt/CBP signalling (Table 1) [20]. 
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Fig. 2. Overview of the high-throughput screen to identify small molecules that promote 
cardiomyogenesis in pluripotent stem cells. Small molecules from a chemical library are 
added to the microtiter plates containing stem cells engineered to express either the 
luciferase or a fluorescent protein under a cardiac-specific promoter.  After several days of 
differentiation, the potential procardiogenic hits are identified based on their ability to 
induce luciferase activity or fluorescence. 
In addition to synthetic small molecules, certain physiological small molecules are capable 
of enhancing ES self-renewal.  For example, Chen, et al. showed evidence that vitamin A 
(retinol) can promote  self-renewal of mES cells in feeder-free conditions by modulating 
Nanog expression [26], a major transcription factor required for pluripotency.   In addition, 
Garcia-Gonzaolo et al demonstrated that the positive effects of Knock-Out Serum 
Replacement (KOSR) on hESC self-renewal are mediated in part through albumin-
associated lipids, although the direct mechanism  remains unclear [27].   
Thus far, a number of synthetic small molecules that promote self-renewal of mouse ES cells 
have been discovered, but none are known to support long-term maintenance of human ESCs 
or iPSCs in chemically defined, animal product-free conditions. Given increasing emphasis on 
human stem cells and the prospect for cell-based therapeutics, there is a substantial unmet 
demand for small molecules for maintenance of human pluripotent stem cells.   
B.  Small molecules for cellular reprogramming   
In many respects, iPS cells are molecularly and functionally indistinguishable from ES cells.  
Like ES cells, they are pluripotent and capable of differentiating into every cell type in the 
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body [8-10, 12].  The early cellular reprogramming methodologies involved viral vector-
mediated transduction of the combinations of either Sox2, Oct4, Klf4 and c-Myc 9, the so-
called “Yamanaka Factors”, or of Sox2, Oct4, Lin28 and Nanog (SOLN) [10].  It is now 
known that Oct4, Sox2 and Klf4 are sufficient for reprogramming [28], with the remaining 
three factors serving to increase reprogramming efficiency.  Since the initial breakthrough in 
mouse embryonic fibroblasts, a number of cell types from variety of mammalian species 
have been successfully reprogrammed into iPS cells [10, 12]. 
Although revolutionary, the early efforts in cellular reprogramming had critical limitations.  
First, the use of lentiviral and retroviral vectors for gene transduction raised the specter of 
oncogenesis, particularly since these early reprogramming methods resulted in permanent 
genomic integration of known oncogenes (c-Myc and klf4).  Second, the early cellular 
reprogramming efforts were extremely inefficient, with only .0006 to 0.02% of transduced 
cells becoming iPS cells, [9, 10, 29].  Subsequent refinements, such as the plasmid-based, 
protein-based and modified RNA-based  strategies, have led to successful virus-free, 
integration-free methods for cellular reprogramming [30-33]. Despite these successes, 
reprogramming remains a largely mysterious and inefficient process. 
There have been important breakthroughs in the use of small molecules to enhance the 
efficiency of cellular reprogramming (Table 2). For example, recognizing that cellular 
reprogramming involves wholesale epigenetic changes, Melton and colleagues used 
valproic acid (VPA), a small molecule histone deacetylase (HDAC) inhibitor, to dramatically 
improve the reprogramming efficiency by 100-fold  without the use of c-Myc in the 
reprogramming cocktail [34].  In a related approach targeting the epigenetic machinery, 
Ding and colleagues used a G9a histone methyltransferase inhibitor, BIX01294, to 
substantially increase reprogramming efficiency of Sox2-expressing mouse neural 
progenitor cells (NPCs) transduced with just two factors, Oct4 and Klf4 (OK), to levels 
obtained with all four Yamanaka factors [35].  In a follow-up screen for small molecules that 
could synergize with BIX01294 to promote reprogramming in mouse embryonic fibroblasts 
transduced with Oct4 and Klf4, Ding and colleagues discovered that RG108, a DNA 
methyltransferase inhibitor, and BayK8644, an L-type calcium channel agonist, could each 
substantially enhance the reprogramming even in the absence of exogenous Sox2 [36]. In 
another approach, Eggan and colleagues sought to identify small molecules that could 
replace one or more of the reprogramming factors, reasoning that such an approach would 
not only reduce potential safety concerns but also enhance reprogramming efficiency.  In a 
screen for small molecules that could replace Sox2 in the reprogramming cocktail, Eggan 
and colleagues identified a small molecule TGF-┚ signaling inhibitor, renamed RepSox, 
which promotes reprogramming via the induction of Nanog, a transcription factor known to 
be critical for self-renewal of ES cells [37].  The findings that an L-type calcium channel 
agonist and a TGF-┚ inhibitor could enhance reprogramming and bypass the need for Sox2 
transduction suggests that a focused approach targeting specific cell signal transduction 
pathways could contribute to further improvements in reprogramming efficiency. Chemical 
biological approaches to enhance reprogramming efficiencies have been successfully 
applied to human somatic cells.  For example, a combination of the small molecules 
SB431542 (an ALK5 inhibitor), PD0325901 (a MEK inhibitor), and thiazovivin (which 
improves the survival of hESCs upon trypsinization) was shown to improve 
reprogramming efficiency of human fibroblasts by 200-fold [38].  These chemical biological 
efforts, in conjunction with improvements in our understanding of the fundamental 
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mechanism of cellular reprogramming and epigenetic modifications, will lead to continual 
improvements in reprogramming methodologies, which will help move the iPSC field closer 
to the clinic.  
C.  Small molecules for directing stem cell differentiation toward cardiomyogenesis.    
For the same reasons that small molecules are proving to be so useful for maintaining stem 
cell self-renewal and enhancing cellular reprogramming, small molecules will play an 
important role in directing differentiation of pluripotent stem cells toward the desired cell 
lineages as well. In principle, small molecules could be used for scaled-up production of 
stem cell-derived tissues for pharmaceutical testing, clinical diagnostics and even patient-
specific cell replacement therapies. Importantly, small molecules can be developed for use as 
pharmacologicals to boost the heart repair and function following stem cell transplantations.  
Given the enormous potential of stem cells with respect to cardiovascular medicine, there 
has been significant interest in identifying small molecules that can promote differentiation 
of pluripotent stem cells toward cardiomyocytic development (Table 3).  
A general approach to identify small molecules that promote cardiac development requires 
high-throughput screens for small molecules that induce cardiomyogenesis in various 
cultured stem cell models (Figure 2). In once such chemical screen, ascorbic acid (vitamin C) 
was found to significantly increase cardiomyogenesis of mouse ESCs. The precise 
mechanism by which ascorbic acid promotes cardiomyogenesis remains unknown, but it 
does not appear to involve ascorbic acid’s well-known antioxidant activity, as other 
antioxidants like 4,5,-dihyroxyl-1,3,-benzene-disulfonic acid (Tiron) vitamin E, and N-
acetylcysteine were not effective in inducing cardiomyogenesis under identical conditions 
[39]. A class of compounds named Cardiogenols is another example of procardiogenic small 
molecules identified in high-throughput screening (HTS) using ES cells.  Treatment of 
mouse ES cells with Cardiogenol C during the initial 3 days of differentiation resulted in 
greater than 50% of cells expressing the a-MHC gene and greater than 90% of cells 
expressing GATA-4 at day 7 of differentiation [40].  While small molecules, like 
Cardiogenols, which are identified in HTS have great potential, one caveat is that 
procardiogenic effects of such compounds can vary depending on culturing conditions [41].   
Nonetheless, Schneider and colleagues recently identified a class of small molecules, called 
Shz for sulfonyl-hydrazones, in a large-scale chemical screen using a Nkx2.5 promoter-
dependent luciferase reporter in pluripotent P19CL6 mouse embryonal carcinoma cell lines 
[42]. The Shz compounds potently induced expression of cardiac markers Nkx-2.5, 
Myocardin, Troponin-I and sarcomeric ┙-Tropomyosin in a number of stem cells and 
progenitor cells. Interestingly, pretreatment of human mobilized peripheral blood 
mononuclear cells (M-PBMCs) with the Shz compounds followed by transplantation into 
injured rat heart lead to significant enhancement in myocardial repair.  While the precise 
mechanism of action is unknown, the Shz compounds could prove to be clinically useful as 
an adjunct to cell-based therapies to repair damaged heart.   
A second general approach to identifying small molecules that promote cardiomyogenesis 
involves testing known small molecules that selectively modulate key developmental 
signaling pathways.  Since it is generally accepted that in vitro cardiomyogenesis in ES cells 
or iPS cells recapitulates many of the events during heart formation in the embryo, using 
small molecules to selectively modulate specific cell signaling events that govern embryonic 
development may be an effective approach to promote cardiomyogenesis in stem cells.  
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Studies in embryonic heart development highlighted the importance of signaling by 
Activins and bone morphogenetic proteins (BMPs), both members of the transforming 
growth factor ┚ (TGF-┚) superfamily, in the formation of mesoderm and in specification of 
myocardial lineages [43-49]. Indeed, the Activin and BMP signaling pathways play key roles 
in the formation of cardiac cells in both human and mouse ES cell models [47, 49].  Based on 
the procardiogenic effects of the natural extracellular BMP antagonist Noggin on ES cells, 
Hong and colleagues demonstrated that dorsomorphin, a selective small molecular inhibitor 
of BMP signaling, was one of the most robust  chemical inducers of cardiomyogenesis in 
mouse ES cells, increasing the yield of cardiomyoctyes by up to 50-fold [50].  Surprisingly, 
dorsomorphin treatment limited to the first 24-hours of ES cell differentiation, fully 2 days 
prior to the robust expression of the early mesoderm marker BryT, was sufficient for 
massive cardiac induction. This, together with the fact that the robust cardiac induction 
occurs in the absence of similar induction of BryT or cardiac progenitor maker Mesp1, 
suggests that the procardiogenic effects of dorsomorphin is mediated by an still unknown 
mechanism. 
Studies of in vitro cardiomyogenesis and in vivo embryonic heart development have revealed 
the central role of canonical Wnt/β-catenin signaling [51, 52].  As in many other contexts, 
Wnt signaling has complex stage-specific effects on cardiomyocyte formation [53, 54].  At 
the early stages of mouse ES cell differentiation, Wnt activation promotes cardiomyogenesis 
presumably by augmenting the formation of mesodermal cells committed to a cardiac 
lineage [55]. But, after the mesoderm formation, Wnt signaling prevents differentiation of 
committed cells into cardiomyocytes [53, 56]. Similar time-dependent biphasic effects of Wnt 
signaling on cardiomyogenesis are also noted in human ES cells [57].  
Given the importance of Wnt// β-catenin signaling in cardiomyogenesis, it is not surprising 
then that selective modulators of this pathway have a strong impact on in vitro 
cardiomyogenesis. For example, 6-bromoindirubin-3’-oxime (BIO), a selective inhibitor of 
GSK-3 which activates Wnt/β-catenin signaling, significantly induced cardiomyocyte 
formation in mouse ES cells when treatment occurred early (day 0 to 3) in ES cell 
differentiation. In contrast, late addition of BIO (starting at day 5) completely abolished the 
expression of cardiac markers and the appearance of spontaneously contracting embryoid 
bodies [56].  Interestingly, the same compound BIO was identified in a HTS screen for small 
molecules that expand postnatal Isl1+ cardiovascular progenitor cells [58], and it was also 
shown to promote proliferation of neonatal and adult rat cardiomyocytes [59]. These 
intriguing results suggest that small molecule Wnt pathway activators like BIO may one day 
be used as pharmacological agents to restore function in the diseased heart. 
Small molecule Wnt signaling inhibitors may also be useful for promoting cardiac 
development.  For example, Hong and colleagues found that a selective small molecule 
inhibitor of Wnt/┚-catenin signaling can also markedly induce cardiomyogenesis in mouse 
ES cells.  When this inhibitor was administered at day 3, immediately after the formation of 
mesoderm, there was a nearly 30-fold induction of cardiomyocyte formation at the expense 
of other mesodermal lineages such as the endothelial and smooth muscle cell lineages (in 
press).  These results hint that small molecule Wnt inhibitors could be useful for promoting 
cardiac differentiation of multipotent cardiovascular progenitor cell types. 
While small molecules have been successful in directing differentiation of embryonic stem 
cells toward the cardiovascular lineage, accumulating evidence suggests that similar efforts 
using iPS cells face additional hurdles. For example, efficiency of cardiomyogenesis in 
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mouse and human iPS cells are significantly lower than for ES cells of respective species [60, 
61]. The mechanism for this appears to be the recently discovered epigenetic memory, which 
stipulates reprogrammed cells tend to differentiate preferentially into tissue types from 
which they were originally derived [62].  Epigenetic memory is particularly germane to the 
cardiovascular field since human adult cardiomyocytes are not suitable substrates for 
reprogramming. Given the breathtakingly rapid advances in the field, however, we 
anticipate small molecules that can overcome epigenetic memory to facilitate differentiation 
of iPS cells into cardiovascular cell types will soon be found.   
3. Summary 
Recent breakthroughs in cellular reprogramming, coupled with the steady stream of 
advances in stem cell biology, have raised expectations for patient-derived stem cells.  It is 
conceivable that they will someday be used for clinical diagnostic testing, drug discovery, 
and regenerative medicine to treat human heart failure, a common yet often fatal condition 
with no known cure.  However, as outlined in this chapter, numerous hurdles must be 
overcome before the regenerative potential of stem cells can be fully harnessed.  
Increasingly, small molecules are being used to successfully overcome each of these 
challenges.  Therefore, it seems reasonable to anticipate that small molecules will prove to 
be essential for translating basic stem cell discoveries into future regenerative therapies.   
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Table 3. Small molecules to promote cardiomyogenesis in pluripotent stem cells. 
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